Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | IDH2 | P48735 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6677604 | 0.95 | PTGER4 (0.32) | PTGER4TP53POLBCA2ADRB3 | |
| SCHEMBL6677114 | 0.92 | CA2 (0.33) | PTGER4TP53POLBCA2ADRB3 | |
| SCHEMBL6676709 | 0.90 | MEN1 (0.32) | PTGER4TP53POLBCA2ADRB3 | |
| SCHEMBL6679724 | 0.89 | PTGER4 (0.32) | PTGER4CA2ADRB3ADRB1IDH2 | |
| SCHEMBL6681055 | 0.88 | PTGER4 (0.35) | PTGER4CA2ADRB3ADRB1 | |
| SCHEMBL6680690 | 0.86 | PTGER4 (0.36) | PTGER4CA2ADRB3ADRB1 | |
| SCHEMBL6804860 | 0.85 | PTGER4 (0.33) | PTGER4TP53POLBADRB3IDH2 | |
| SCHEMBL6804852 | 0.85 | PTGER4 (0.33) | PTGER4TP53POLBADRB3IDH2 | |
| SCHEMBL6677699 | 0.84 | ADRB3 (0.37) | CA2ADRB3ADRB1ADRB2 | |
| SCHEMBL6676570 | 0.81 | PTGER4 (0.33) | PTGER4TP53POLBADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004045610-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-06-03 | — | — | WO | disclosed |